BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

CureVac N.V. (NASDAQ:CVAC) is among the 13 Best German Stocks to Invest in Now. The stock has gained by over 16% in the past month, with a major surge following the June 12 announcement that the ...

BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases. On ...

Detailed price information for America's Car-Mart (CRMT-Q) from The Globe and Mail including charting and trades.

On June 12, 2025, BioNTech SE (“BioNTech”) announced its entry into a definitive purchase agreement to acquire all shares of CureVac N.V. (“CureVac”), with an implied aggregate equity ...

Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the ...

Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter ...

German vaccine manufacturer BioNTech has acquired its domestic competitor CureVac, taking over all of its shares in a transaction that values the company at approximately $1.25 billion. Mainz ...

BioNTech SE and CureVac N.V. announced that they have entered into a definitive purchase agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage ...

COVID-19 patients who are vaccinated -- and were hospitalized with reduced kidney function -- had better outcomes than unvaccinated patients, a new study finds.